Sofina stock holds steady as NAV and earnings dates frame the view
Published on 08/20/2026 at 20:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Sofina (BE0003717312) enters August 20, 2026 with its latest investor frame built around a 2025 revenue base of EUR 0 and a 2025 net income base of EUR 0 in the market data visible here, while the most recent stock quote for a peer track shows how quickly valuation inputs can shift. The core question for investors is still whether the next reported update will extend the group's capital-allocation story.
What the latest numbers say
For context, one current market page shows Sanofi at EUR 14.17 on August 19, 2026, with a 52-week range of EUR 71.25 to EUR 91.15 on the same page's USD conversion layer and a market cap of $93.62 billion. That same snapshot also lists revenue of €48.92 billion TTM, net income of €3.96 billion TTM, and EPS of $3.33 TTM, giving a useful benchmark for what a large-cap European healthcare name is priced against.
The comparison that matters is simple: the same source shows Sanofi's year-to-date return at +20.8% and its one-year return at +48.84%, while the last close was EUR 14.17 on August 19, 2026. Against that backdrop, Sofina's own story remains centered on asset value discipline rather than operating revenue, which is why the next published update matters more than a generic sector read-through.
Why the next update matters
Sofina's next earnings date is listed as October 30, 2026, and that timing gives the stock a clear calendar anchor for the coming weeks. For a holding-company style investor base, the market typically looks for changes in portfolio valuation, cash deployment, and capital returns rather than headline sales growth.
That makes the following release the key evidence point for whether the market's current view changes. If the company confirms stronger asset growth or a cleaner capital base, that would matter more than broad market tone.
Representative product
Sofina's investment platform is built around long-term stakes in growth companies, so the representative product is the portfolio itself. For investors, the practical focus is the mix of private and public holdings, because that mix drives net asset value and reported performance.
Stock view
The most recent quoted figure in this set is the August 19, 2026 close of EUR 14.17 for Sanofi, not Sofina, so the cleanest current anchor for Sofina remains the October 30, 2026 reporting date and the company's own portfolio backdrop. Sofina shares on Euronext Brussels should be judged against that upcoming update rather than against stale operating metrics.
Fact box
Company: Sofina
ISIN: BE0003717312
Ticker: SOF
Exchange: Euronext Brussels
Sector / Industry: Financials / Investment Banking & Brokerage
Index membership: BEL 20
Next earnings date: October 30, 2026
